NCT05728840 Virtual-reality Exercises for Alleviating Attention Deficits in Patients With Acquired Brain Injury
| NCT ID | NCT05728840 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mindmaze SA |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 135 participants |
| Start Date | 2023-02-15 |
| Primary Completion | 2026-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 135 participants in total. It began in 2023-02-15 with a primary completion date of 2026-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Stroke is the leading cause of long-term disability with an increasing incidence, especially in young adults. Among the cognitive difficulties following brain damage, deficits in attention are frequent and pervasive, affecting between 46% and 92% of stroke survivors. The current project targets patients with acquired brain injury, including stroke, traumatic brain injury, and brain tumor. The main objective of this study is to evaluate the use and the efficacy of a training program targeting attention and executive function difficulties, using gamified and digitized versions in virtual reality of standard cognitive exercises for patients with brain lesions.
Eligibility Criteria
Inclusion Criteria: * Time from stroke onset \< 1 month * Objective pathological performance on at least one standardized test or subtest on attention during standard neuropsychological evaluation * Brain injury documented by routine neuroradiological examination (computed tomography or magnetic resonance imaging scan) * Able to give informed consent as documented by signature * Age \>= 18 years old Exclusion Criteria: * Epilepsy * Inability or contraindications to undergo the investigated intervention * Major psychiatric co-morbidity * Major neurocognitive deficits (e.g. dementia) * Incapacity to discriminate colors * General cognitive state preventing to understand and perform the tasks * Decision to not be informed of incidental findings
Contact & Investigator
Sonia Crottaz-Herbette
PRINCIPAL INVESTIGATOR
University of Lausanne Hospitals
Frequently Asked Questions
Who can join the NCT05728840 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05728840 currently recruiting?
Yes, NCT05728840 is actively recruiting participants. Contact the research team at sonia.crottaz-herbette@chuv.ch for enrollment information.
Where is the NCT05728840 trial being conducted?
This trial is being conducted at Lausanne, Switzerland.
Who is sponsoring the NCT05728840 clinical trial?
NCT05728840 is sponsored by Mindmaze SA. The principal investigator is Sonia Crottaz-Herbette at University of Lausanne Hospitals. The trial plans to enroll 135 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.